This just popped up in my morning reading: Practice Update Prostate Cancer feed. I'll leave it to the wiser HU minds to determine if the findings are based on solid research:
practiceupdate.com/content/...
TAKE-HOME MESSAGE This study aimed to develop a prognostic model to predict the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) by using patient data from the control arms of five randomized clinical trials (ASCENT 2, VENICE, CELGENE/MAINSAIL, ENTHUSE 14, and ENTHUSE 33). The cohort was divided into two groups: a training cohort, which included 70% of the patients in the original cohort, and a validation cohort, which included the remaining 30% of the patients in the original cohort. On multivariate analysis, the following variables were noted to be predictive of OS: alkaline phosphatase levels, PSA levels, aspartate transaminase levels, BMI, hemoglobin levels, and sites of metastasis (visceral vs bone). In addition, the nomogram that was developed based on these variables showed good discrimination and calibration on external validation.This prognostic model could be used as a tool for risk stratification of patients with mCRPC in practice and clinical trials.